BIAF Stock Pops As CyPath Lung Wins Federal Distribution

bioAffinity Technologies Inc. stocks have been trading up by 18.25 percent following highly positive coverage of its cancer diagnostics progress.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BIAF

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For BIAF Traders

Nationwide agreement with AvMEDICAL gives CyPath Lung direct access to VA and other federal healthcare systems through established IDIQ contracting and a government-focused sales team.
New AvMEDICAL deal leverages existing federal procurement channels, streamlining BIAF’s entry into the Department of Veterans Affairs and related U.S. government healthcare networks.
The company is pushing CyPath Lung beyond early detection into post-treatment surveillance, targeting lung cancer survivors for recurrence and new primary cancer monitoring.
Management is exploring survivorship surveillance as an added CyPath Lung use case, addressing a high‑risk population currently dependent on periodic imaging alone.
Leadership will present a corporate update and hold one‑on‑ones at the H.C. Wainwright Global Investment Conference, emphasizing CyPath Lung adoption and platform expansion.

Live Update At 08:32:20 EDT: On Wednesday, September 09, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 18.25%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIAF has been trading like a classic low‑float biotech in play. In late August, bioAffinity Technologies Inc. shares sat under $5, closing at $4.56 on 2026/08/31. Within days, BIAF exploded. By 2026/09/04, the stock printed a high near $20.35 and closed at $15.27. Even after a pullback to $8.93 on 2026/09/08, BIAF still locked in a huge multi-day move.

Intraday, the 5‑minute chart shows aggressive trading ranges. On the latest tape, BIAF swung from the high $8s in premarket to above $11 before settling just over $10.50. That kind of intraday range is catnip for momentum traders who know how to cut losses fast.

Fundamentals tell a different, more cautious story. bioAffinity Technologies generated about $6.1M in revenue over the trailing period, with a solid 52.6% gross margin, but extremely negative profitability metrics. EBITDA for the latest reported quarter (period ending 2026/06/30) came in around -$3.29M, and net income was roughly -$3.37M, or -$0.64 per share. BIAF is clearly a high‑burn growth story, not a value play.

More Breaking News

On the balance sheet, BIAF shows about $2.4M in cash and a current ratio around 1.4, giving it some short‑term breathing room but not endless runway. With price-to-sales near 1.6 and price-to-book around 2.4, traders are paying up for pipeline potential and the CyPath Lung ramp, not current earnings.

Why Traders Are Watching BIAF Now

The core driver behind BIAF’s recent surge is news‑flow, not earnings. bioAffinity Technologies locked in a nationwide federal healthcare distribution agreement with AvMEDICAL for its CyPath Lung noninvasive lung cancer diagnostic. For traders, this is the kind of clear, concrete catalyst that justifies the big volume spikes on the daily chart.

Here’s why it matters. The AvMEDICAL deal gives BIAF direct access to the Department of Veterans Affairs and other federal healthcare systems through an established government-focused sales force and IDIQ contracting channels. BIAF is not trying to learn the VA procurement maze from scratch. Instead, bioAffinity Technologies is plugging into AvMEDICAL’s existing infrastructure, from purchasing systems to on-the-ground reps already calling on VA hospitals and federal clinics.

That shortcut can accelerate real‑world adoption of CyPath Lung. If VA sites begin ordering the test for veterans at high risk of lung cancer, BIAF could see meaningfully higher test volumes and clearer reimbursement patterns. Traders love that kind of visibility. It lowers perceived commercial risk and helps justify the sharp re‑rating we’ve seen on the chart.

At the same time, bioAffinity Technologies is expanding CyPath Lung’s clinical story. Originally positioned for early detection, BIAF is now pushing into post-treatment surveillance of lung cancer survivors. These are patients with high recurrence risk who today often rely on periodic imaging alone. CyPath Lung, as a sputum-based adjunct, sets up a recurring testing model: same patient, many tests over years. For traders, that’s a “pipeline within a product” angle that can support longer‑term revenue narratives.

Finally, bioAffinity Technologies is taking this story to the street. BIAF will present a corporate update and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference. Conferences like this often act as catalysts. Any color on VA uptake, survivorship data, or broader platform use cases can move sentiment fast in a thinly traded name like BIAF.

Conclusion

BIAF is a textbook example of how news drives small-cap biotech price action. On one side, bioAffinity Technologies is burning cash, with negative margins and heavy operating losses as it funds commercialization and R&D. On the other, the company just secured a powerful commercialization lever in federal healthcare and is carving out new clinical territory for CyPath Lung.

For active traders, the setup is straightforward but demanding. BIAF has already shown it can sprint from sub‑$5 levels to above $15 in days. The daily and intraday charts confirm wild ranges, fast halts, and big gaps. That volatility offers opportunity, but it punishes hesitation and oversized positions. The fundamentals say BIAF still depends heavily on future execution — VA adoption, survivorship use, and broader platform expansion — not current cash generation. In a name like this, trade planning matters as much as trade execution; as Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” That framework is crucial when you’re dealing with a thinly traded, catalyst-driven small-cap like BIAF.

bioAffinity Technologies will keep working the conference circuit and pushing data to support CyPath Lung both in early detection and post‑treatment surveillance. Each new update can reset the trading range. As Tim Sykes often says, “The pattern is your edge, not the hype.” For anyone trading BIAF, that means respecting the chart, honoring tight risk, and treating every headline as a potential catalyst — not a guarantee. This analysis is for educational and research purposes only, and every trader must make their own decisions.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!